Pluss Advanced Technologies (PLUSS), India has partnered with The Rodnight Partnership to increase the availability of its MiraCradle neonatal cooling device in the African Union and other developing nations.

MiraCradle is said to be the world’s first non-electronic, portable device for the treatment of infants born with a condition called birth asphyxia.

The collaboration is expected to ensure timely treatment, especially in the African Union, Middle East and South East Asia.

Developed in collaboration with Christian Medical College, Vellore in India, the device induces therapeutic hypothermia among newborns suffering from birth asphyxia, which is the recommended medical treatment.

The British Medical Journal and International Journal of Paediatric Research, among other publications, have reported on its clinical effectiveness.

The technology, based on phase change materials technology, is also listed in the National Library of Medicine (NLM).

During the infant treatment, the baby is placed on the MiraCradle device. It absorbs the body heat and keeps the infant cool for up to 72 hours without the need for electricity while in use.

Pluss Advanced Technologies Lifesciences VP and business head Udit Mangal said: “MiraCradle offers a safe, more controlled and low-cost cooling compared to servo-controlled cooling equipment.

“It would be particularly significant for facilities that are resource constrained, and where travel distances to tertiary care centres might be substantial. We are happy to partner with The Rodnight Partnership to enhance the availability of this device in the Global South.

“We have also received interest from a number of manufacturers for licensing this technology and are actively evaluating it to further the worldwide availability of MiraCradle.”

In addition, MiraCradle was given a patent in the US, EU, Brazil, South Africa, Malaysia, and India and is listed in the WHO compendium of Affordable Innovative Health Technologies.

The Rodnight Partnership supports international business endeavours of medical manufacturing firms.

This programme supports the G20 declaration, which calls for supporting equal access to medications and diagnostics that are safe, effective, and reasonably priced, particularly in low- and middle-income nations.